Which patient subgroups that, based on the Odyssey Outcomes Trial, could benefit significantly from a PCSK9 inhibitor, in your observation, are not getting treatment consistently enough—i.e. are being “under-treated”—with these agents?
Which patient subgroups that, based on the Odyssey Outcomes Trial, could benefit significantly from a PCSK9 inhibitor, in your observation, are not getting treatment consistently enough—i.e. are being “under-treated”—with these agents?
Created by
Presenter
Full Professor of Pharmacology University of Milano Director, Laboratory for the Study of Lipoproteins and Atherosclerosis Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis